SAN DIEGO, Sept. 27, 2018 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced that members of the leadership team will
present at the following upcoming investor conferences in
New York City:
Tuesday, October 2,
10:30 a.m. ET
Ladenburg
Thalmann 2018 Healthcare Conference
Presenter: Chief Executive Officer Marty
Duvall
Wednesday, October 3,
8:00 a.m. ET
Cantor Global
Healthcare Conference
Presenter: Chief Executive Officer Marty
Duvall
Wednesday, October 3,
9:00 a.m. ET
Leerink
Roundtable Series: Rare Disease & Oncology
Presenters: Chief Financial Officer Mark
Foletta and Chief Medical Officer Asha Das, M.D.
Tuesday, October 9,
3:45 p.m. ET
Chardan Capital
Markets 2nd Annual Genetic Medicines Conference
Presenter: Chief Executive Officer Marty
Duvall
The live audio webcasts from the conferences and subsequent
replay may be accessed by visiting the "Events &
Presentations" page in the investors section of
Tocagen's website. The webcasts will be available shortly
after conclusion of the presentation and archived on the company's
website for 90 days following the presentation.
About Tocagen Inc.
Tocagen is a clinical-stage,
cancer-selective gene therapy company developing first-in-class,
broadly applicable product candidates designed to activate a
patient's immune system against their own
cancer. Tocagen's lead investigational product candidate,
Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3
trial for recurrent high grade glioma (HGG), a disease with
significant unmet medical need. The U.S. Food and Drug
Administration (FDA) has granted Toca 511 & Toca FC
Breakthrough Therapy Designation for the treatment of recurrent HGG
and the European Medicines Agency (EMA) has granted Toca
511 PRIME (PRIority MEdicines) designation for the treatment of
glioma. For more information about Tocagen,
visit www.tocagen.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-participate-in-four-investor-conferences-in-october-300720474.html
SOURCE Tocagen Inc.